Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates
Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics Q3 EPS $(0.12) Misses $0.04 Estimate, Sales $5.647M Miss $29.000M Estimate
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.